Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569108 | 0.88 | TDP1 (0.41) | KMT2APOLBALDH1A1 | |
| SCHEMBL16108220 | 0.86 | TDP1 (0.52) | KMT2AMEN1POLBNPC1RAB9A | |
| SCHEMBL16108819 | 0.84 | KMT2A (0.47) | NPBWR1KMT2AMEN1POLBNPC1 | |
| SCHEMBL16108174 | 0.84 | KMT2A (0.47) | NPBWR1KMT2AMEN1POLBNPC1 | |
| SCHEMBL16108281 | 0.84 | KMT2A (0.47) | KMT2AMEN1POLBNPC1RAB9A | |
| SCHEMBL16108208 | 0.84 | SMN1; SMN2 (0.47) | KMT2AMEN1POLBNPC1RAB9A | |
| SCHEMBL16108415 | 0.82 | ALDH1A1 (0.47) | NPBWR1KMT2AMEN1POLBNPC1 | |
| SCHEMBL16108265 | 0.81 | BACE1 (0.59) | NPBWR1KMT2AMEN1POLBNPC1 | |
| SCHEMBL16108933 | 0.81 | CNR1 (0.54) | KMT2AMEN1POLBNPC1RAB9A | |
| SCHEMBL16108168 | 0.81 | KMT2A (0.45) | KMT2AMEN1POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014160775-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | SAINT LOUIS UNIVERSITY (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | claimed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | NPBWR1 3333/4885KMT2A 960/4885MEN1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.